Allen Jeffrey A, Adlakha Ashish, Bergethon Peter R
Department of Neurology, Tufts -- New England Medical Center, Boston, Mass, USA.
Arch Neurol. 2006 Oct;63(10):1475-8. doi: 10.1001/archneur.63.10.1475.
To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.
Case report/literature review.
University hospital.
A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.
Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.
描述一名在使用贝伐单抗（阿瓦斯汀）（一种抗血管内皮生长因子的单克隆抗体）后出现可逆性后部白质脑病综合征的患者。
病例报告/文献综述。
大学医院。
一名52岁男性，因IV期直肠癌接受化疗。
在给予盐酸伊立替康、亚叶酸钙和氟尿嘧啶（FOLFIRI）方案化疗及贝伐单抗后，发现了与可逆性后部白质脑病综合征相符的临床和影像学证据。
使用血管生成调节剂治疗后可能发生可逆性后部白质脑病综合征。除了提高对合适患者的临床怀疑外，本报告可能为可逆性后部白质脑病综合征的病理生理基础提供线索。
